Intrapartum management of category II fetal heart rate tracings: towards standardization of care.

There is currently no standard national approach to the management of category II fetal heart rate (FHR) patterns, yet such patterns occur in the majority of fetuses in labor. Under such circumstances, it would be difficult to demonstrate the clinical efficacy of FHR monitoring even if this technique had immense intrinsic value, since there has never been a standard hypothesis to test dealing with interpretation and management of these abnormal patterns. We present an algorithm for the management of category II FHR patterns that reflects a synthesis of available evidence and current scientific thought. Use of this algorithm represents one way for the clinician to comply with the standard of care, and may enhance our overall ability to define the benefits of intrapartum FHR monitoring.

Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop.

In August 2007, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institutes of Health Office of Rare Diseases, the American College of Obstetricians and Gynecologists, and the American Academy of Pediatrics cosponsored a 2-day workshop to reassess the body of evidence supporting antepartum assessment of fetal well-being, identify key gaps in the evidence, and formulate recommendations for further research. Participants included experts in obstetrics and fetal physiology and representatives from relevant stakeholder groups and organizations. This article is a summary of the discussions at the workshop, including synopses of oral presentations on the epidemiology of stillbirth and fetal neurological injury, fetal physiology, techniques for antenatal monitoring, and maternal and fetal indications for monitoring. Finally, a synthesis of recommendations for further research compiled from three breakout workgroups is presented.

Antepartum testing in patients with hypertensive disorders in pregnancy.

Antepartum fetal testing in pregnant patients with hypertensive disorders may be beneficial in preventing stillbirth and hypoxic sequelae in the fetus. The highest risk patients in this category are those with intrauterine growth restriction, superimposed preeclampsia, associated medical complications such as diabetes, systemic lupus erythematosis, chronic renal disease, or history of a prior stillbirth. The current recommended method of primary testing is a twice weekly modified biophysical profile with either a full BPP or a contraction stress test for backup evaluation of those patients with lack of reactivity or decreased amniotic fluid volume on a modified biophysical profile. Even uncomplicated patients with chronic hypertension or pregnancy-induced hypertension carry an increased risk of perinatal mortality and for these patients testing should begin at 33 to 34 weeks gestation. Patients with complications of intrauterine growth restriction, preeclampsia, diabetes, systemic lupus erythematosis, or chronic renal disease should have antepartum testing begin when intervention for fetal indications is judged to be appropriate, usually beginning at about 26 weeks gestation. Doppler velocimetry may be helpful in further evaluation of those patients in the early third trimester with abnormal primary testing.

Signal ambiguity resulting in unexpected outcome with external fetal heart rate monitoring.

We report cases of unexpected adverse fetal outcome from monitored labors in which the fetal heart rate tracing was interpreted as reassuring. In these cases, portions from another signal source, usually maternal, were imperceptibly substituted into the fetal tracing in a way that masked the evidence of fetal compromise.

Problems with intrapartum fetal heart rate monitoring interpretation and patient management.

Fetal heart rate (FHR) monitoring was introduced over 3 decades ago into clinical use and patient management. It continues to be the predominant method for intrapartum fetal surveillance despite questions about its efficacy and outcomes associated with its use. Currently, there appears to be a consensus regarding the reassuring value of a normal reactive pattern without decelerations. Patterns containing absent variability associated with persistent late decelerations, severe variable decelerations, and prolonged decelerations are generally believed to be ominous and may correlate with hypoxia of such severity that fetal central nervous system (CNS) damage may already have occurred. The clinician, however, is faced with FHR patterns between these extremes, and there appears to be a lack of consensus about their management. Furthermore, there is recent evidence that a fetal inflammatory response may lead to CNS damage, and the FHR patterns associated with this condition are not yet understood nor are there any intervention strategies that have been shown to benefit such fetuses. This article is an attempt to illustrate these situations and offer an approach useful to the clinician faced with such FHR patterns.